×
About 4,644 results

ALLMedicine™ Sickle Cell Anemia Center

Research & Reviews  2,185 results

Oxidative stress, inflammation, blood rheology and microcirculation in adults with sick...
https://doi.org/10.1111/ejh.13607
European Journal of Haematology; Connes P, Möckesch B et. al.

Feb 25th, 2021 - Inflammation and oxidative stress play a key role in the pathophysiology of sickle cell disease (SCD). However, the potential influence of different sickle genotypes, or hydroxyurea (HU) treatment on these factors remains poorly documented. The pr...

Transcranial Doppler Screening in a Current Cohort of Children With Sickle Cell Anemia:...
https://doi.org/10.1097/MPH.0000000000002103
Journal of Pediatric Hematology/oncology; Kanter J, Phillips S et. al.

Feb 24th, 2021 - Stroke prevention guidelines for sickle cell anemia (SCA) recommend transcranial Doppler (TCD) screening to identify children at stroke risk; however, TCD screening implementation remains poor. This report describes results from Part 1 of the 28-s...

Efficient Clinical Counseling for Sickle Cell Disease.
https://doi.org/10.1016/j.jnma.2021.01.006
Journal of the National Medical Association; Morrone KA, Manwani D et. al.

Feb 21st, 2021 - Sickle cell anemia (SCA) is a chronic illness that requires frequent health care visits for preventative management. Adherence to national guidelines such as the National Heart Lung and Blood Institute (NHLBI) Expert Panel Report on the Evidence-B...

Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical ...
https://doi.org/10.1007/s00277-021-04450-x 10.1100/2012/949535 10.1101/cshperspect.a011783 10.1080/03630260701290233 10.1182/blood.V68.5.985.985 10.1016/S0889-8588(18)30426-X 10.1590/S1516-84842007000300003 10.1590/S1516-84842010005000005 10.1590/S1415-475738320140231 10.1111/j.1365-2141.2005.05411.x 10.1016/j.blre.2006.07.001 10.1182/blood-2005-04-1594 10.1111/j.1365-2141.2007.06643.x 10.1586/ehm.10.44 10.1016/j.jpeds.2011.07.018 10.4084/mjhid.2015.060 10.1016/S0022-3476(05)80897-2 10.3109/03630268908998842 10.1100/tsw.2009.10 10.1111/j.1600-0609.2011.01705.x 10.1172/JCI89741 10.1182/blood-2011-03-325258 10.1002/jmri.24785.Free-Breathing 10.1056/NEJM198504043121403 10.1111/j.1600-0609.2010.01528.x 10.1073/pnas.81.6.1771 10.1002/1096-8652(200011)65:3<192::AID-AJH3>3.0.CO;2-N 10.1056/NEJMra1510865 10.1002/ajh.23232 10.1097/00043426-199023000-00022 10.1016/j.cupe.2004.10.009 10.1590/S1415-47572011005000027 10.5581/1516-8484.20130048 10.1073/pnas.0611393104 10.1073/pnas.0711566105 10.1177/1535370216642047 10.1007/s40291-018-0370-8 10.1182/blood.V85.4.1111.bloodjournal8541111 10.1159/000320271 10.1056/NEJM198606193142501 10.1056/nejm199505183322001 10.1182/blood-2005-02-0548 10.1111/j.1365-2141.2004.05295.x 10.1111/j.1365-2141.2006.06074.x 10.1002/ajh.2830320113 10.1111/j.1365-2141.1993.tb04639.x 10.3233/CH-189012 10.1016/j.blre.2015.12.003 10.1182/bloodadvances.2019000193 10.3233/CH-189009 10.3109/03630269.2010.526003 10.1590/S1415-47572008000400003 10.1034/j.1600-0609.2000.90210.x 10.1182/blood.V84.2.643.643 10.1002/(SICI)1096-8652(200006)64:2<87::AID-AJH2>3.0.CO;2-B 10.1182/blood.V74.4.1403.1403 10.1002/ajh.2830450402 10.1182/blood-2011-01-332205 10.1111/ejh.12607 10.1186/1471-2350-4-6 10.1016/S0037-1963(01)90023-X 10.1002/ajh.10140 10.1097/01.sla.0000242716.66878.23 10.1159/000040890 10.1002/ajh20574 10.1056/NEJM198206173062402 10.5045/kjh.2011.46.3.192 10.1002/ajh.21838 10.1016/j.bjhh.2014.06.002 10.1002/jcla.22656 10.1371/journal.pone.0100516 10.1016/j.hoc.2013.11.006 10.1002/ajh.23711 10.1182/blood.V64.5.1042.1042 10.1056/NEJM199406093302303 10.1056/NEJM200005253422114 10.1097/01.md.0000189089.45003.52 10.1186/1471-2156-8-52 10.1007/s00277-020-04048-9 10.1002/ajpa.1330880304 10.1002/(SICI)1096-8652(199610)53:2<72::AID-AJH3>3.0.CO;2-0 10.1002/ajhb.21047 10.1590/S1516-84842010000100017 10.4236/ojbd.2014.42003 10.5935/1676-2444.20160001 10.1001/archpedi.1993.02160350071011 10.1002/ajh.2830360305 10.1016/j.bcmd.2012.12.005 10.1073/pnas.0804799105 10.1080/03630260601057153 10.1590/S0100-879X2003001000001 10.1081/HEM-120040310 10.1016/j.jped.2016.01.010 10.1089/omi.2014.0134 10.1182/bloodadvances.2017014555
Annals of Hematology; Hatzlhofer BLD, Pereira-Martins DA et. al.

Feb 15th, 2021 - Alpha thalassemia and beta-globin haplotype are considered classical genetic disease modifiers in sickle cell anemia (SCA) causing clinical heterogeneity. Nevertheless, their functional impact on SCA disease emergence and progression remains elusi...

Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805333
Blood Advances; Rai P, Joshi VM et. al.

Feb 11th, 2021 - Elevated tricuspid regurgitant velocity (TRV) ≥2.5 m/s is a predictor of disease severity in adults and children with sickle cell anemia (SCA), but how disease-modifying therapies (DMTs) affect this biomarker is incompletely understood. We investi...

see more →

Guidelines  23 results

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
http://www.bloodjournal.org/content/early/2019/01/17/blood-2018-08-868893?sso-checked=true
Howard,J,et al

Jan 16th, 2019 - New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe morbidity and early mortality associated with the disease. Voxel...

Statement on Opioid Use in Patients with Hematologic Diseases and Disorders
http://www.hematology.org/Advocacy/Statements/8502.aspx
American Society of Hematology

Apr 17th, 2018 - According to the Centers for Disease Control and Prevention, overdoses from prescription opioids in the United States have contributed to the 15-year increase in opioid overdose deaths and nearly half of all opioid overdose deaths involve a prescr.

Pain Management in Vaso-occlusive Sickle Cell Crisis
https://www.emra.org/emresident/article/pain-management-in-vaso-occlusive-sickle-cell-crisis/
Amani Mahdi

Apr 10th, 2017 - To optimize patient care, considerable effort must be directed toward understanding the pathophysiology of SCD, appreciating the severity of each episode, and anticipating the likelihood of VOC recurrence. In addition, the patient's age, comorbidi.

Pediatric Pulmonary Hypertension
http://www.thoracic.org/statements/resources/pldd/pediatric-pulmonary-hypertension.pdf
Steven H. Abman

Mar 14th, 2016 - Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, and older children and contributes to significant morbidity and mortality. However, current approaches to caring for pediatric patien.

Health Maintenance and Management of Chronic Complications of Sickle Cell Disease: ASH Guide...
http://ashpocketguides.hematology.org/#/app/guides/3/pages/
American Society of Hematology

Oct 31st, 2014 - Guide for Health Maintenance and Management of Chronic Complications of Sickle Cell Disease.

see more →

Drugs  3 results see all →

Clinicaltrials.gov  2,293 results

Oxidative stress, inflammation, blood rheology and microcirculation in adults with sick...
https://doi.org/10.1111/ejh.13607
European Journal of Haematology; Connes P, Möckesch B et. al.

Feb 25th, 2021 - Inflammation and oxidative stress play a key role in the pathophysiology of sickle cell disease (SCD). However, the potential influence of different sickle genotypes, or hydroxyurea (HU) treatment on these factors remains poorly documented. The pr...

Transcranial Doppler Screening in a Current Cohort of Children With Sickle Cell Anemia:...
https://doi.org/10.1097/MPH.0000000000002103
Journal of Pediatric Hematology/oncology; Kanter J, Phillips S et. al.

Feb 24th, 2021 - Stroke prevention guidelines for sickle cell anemia (SCA) recommend transcranial Doppler (TCD) screening to identify children at stroke risk; however, TCD screening implementation remains poor. This report describes results from Part 1 of the 28-s...

Efficient Clinical Counseling for Sickle Cell Disease.
https://doi.org/10.1016/j.jnma.2021.01.006
Journal of the National Medical Association; Morrone KA, Manwani D et. al.

Feb 21st, 2021 - Sickle cell anemia (SCA) is a chronic illness that requires frequent health care visits for preventative management. Adherence to national guidelines such as the National Heart Lung and Blood Institute (NHLBI) Expert Panel Report on the Evidence-B...

Droxia - hydroxyurea capsule-E.R. Squibb & Sons, L.L.C.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=740e054b-faac-7c27-f06d-a56efb699355

Feb 21st, 2021 - DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises. DROXIA is an antimetabolite indicated to reduce the f...

Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical ...
https://doi.org/10.1007/s00277-021-04450-x 10.1100/2012/949535 10.1101/cshperspect.a011783 10.1080/03630260701290233 10.1182/blood.V68.5.985.985 10.1016/S0889-8588(18)30426-X 10.1590/S1516-84842007000300003 10.1590/S1516-84842010005000005 10.1590/S1415-475738320140231 10.1111/j.1365-2141.2005.05411.x 10.1016/j.blre.2006.07.001 10.1182/blood-2005-04-1594 10.1111/j.1365-2141.2007.06643.x 10.1586/ehm.10.44 10.1016/j.jpeds.2011.07.018 10.4084/mjhid.2015.060 10.1016/S0022-3476(05)80897-2 10.3109/03630268908998842 10.1100/tsw.2009.10 10.1111/j.1600-0609.2011.01705.x 10.1172/JCI89741 10.1182/blood-2011-03-325258 10.1002/jmri.24785.Free-Breathing 10.1056/NEJM198504043121403 10.1111/j.1600-0609.2010.01528.x 10.1073/pnas.81.6.1771 10.1002/1096-8652(200011)65:3<192::AID-AJH3>3.0.CO;2-N 10.1056/NEJMra1510865 10.1002/ajh.23232 10.1097/00043426-199023000-00022 10.1016/j.cupe.2004.10.009 10.1590/S1415-47572011005000027 10.5581/1516-8484.20130048 10.1073/pnas.0611393104 10.1073/pnas.0711566105 10.1177/1535370216642047 10.1007/s40291-018-0370-8 10.1182/blood.V85.4.1111.bloodjournal8541111 10.1159/000320271 10.1056/NEJM198606193142501 10.1056/nejm199505183322001 10.1182/blood-2005-02-0548 10.1111/j.1365-2141.2004.05295.x 10.1111/j.1365-2141.2006.06074.x 10.1002/ajh.2830320113 10.1111/j.1365-2141.1993.tb04639.x 10.3233/CH-189012 10.1016/j.blre.2015.12.003 10.1182/bloodadvances.2019000193 10.3233/CH-189009 10.3109/03630269.2010.526003 10.1590/S1415-47572008000400003 10.1034/j.1600-0609.2000.90210.x 10.1182/blood.V84.2.643.643 10.1002/(SICI)1096-8652(200006)64:2<87::AID-AJH2>3.0.CO;2-B 10.1182/blood.V74.4.1403.1403 10.1002/ajh.2830450402 10.1182/blood-2011-01-332205 10.1111/ejh.12607 10.1186/1471-2350-4-6 10.1016/S0037-1963(01)90023-X 10.1002/ajh.10140 10.1097/01.sla.0000242716.66878.23 10.1159/000040890 10.1002/ajh20574 10.1056/NEJM198206173062402 10.5045/kjh.2011.46.3.192 10.1002/ajh.21838 10.1016/j.bjhh.2014.06.002 10.1002/jcla.22656 10.1371/journal.pone.0100516 10.1016/j.hoc.2013.11.006 10.1002/ajh.23711 10.1182/blood.V64.5.1042.1042 10.1056/NEJM199406093302303 10.1056/NEJM200005253422114 10.1097/01.md.0000189089.45003.52 10.1186/1471-2156-8-52 10.1007/s00277-020-04048-9 10.1002/ajpa.1330880304 10.1002/(SICI)1096-8652(199610)53:2<72::AID-AJH3>3.0.CO;2-0 10.1002/ajhb.21047 10.1590/S1516-84842010000100017 10.4236/ojbd.2014.42003 10.5935/1676-2444.20160001 10.1001/archpedi.1993.02160350071011 10.1002/ajh.2830360305 10.1016/j.bcmd.2012.12.005 10.1073/pnas.0804799105 10.1080/03630260601057153 10.1590/S0100-879X2003001000001 10.1081/HEM-120040310 10.1016/j.jped.2016.01.010 10.1089/omi.2014.0134 10.1182/bloodadvances.2017014555
Annals of Hematology; Hatzlhofer BLD, Pereira-Martins DA et. al.

Feb 15th, 2021 - Alpha thalassemia and beta-globin haplotype are considered classical genetic disease modifiers in sickle cell anemia (SCA) causing clinical heterogeneity. Nevertheless, their functional impact on SCA disease emergence and progression remains elusi...

see more →

News  125 results

Hydroxyurea Dose Escalation Safe, More Effective Against Childhood Sickle Cell Anemia
https://www.staging.medscape.com/viewarticle/932935

Jun 25th, 2020 - (Reuters Health) - Raising the dose of hydroxyurea by roughly 50% for children with sickle cell anemia dramatically lowers the risk of sickle-cell complications, according to a new study of 187 Ugandan children published in the New England Journal...

Hydroxyurea Dose Escalation Safe, More Effective Against Childhood Sickle Cell Anemia
https://www.medscape.com/viewarticle/932935

Jun 25th, 2020 - (Reuters Health) - Raising the dose of hydroxyurea by roughly 50% for children with sickle cell anemia dramatically lowers the risk of sickle-cell complications, according to a new study of 187 Ugandan children published in the New England Journal...

FDA approves Global Blood Therapeutics sickle cell disease drug
https://www.reuters.com/article/us-global-blood-theraprutics-fda/fda-approves-global-blood-therapeutics-sickle-cell-disease-drug-idUSKBN1XZ2E5

Nov 25th, 2019 - (Reuters) - The U.S. Food and Drug Administration said on Monday it approved a drug from Global Blood Therapeutics Inc to treat sickle cell disease in adults and children 12 years or older. The treatment will be priced at $10,417 per month, or aro...

Suicide trends among youth on Medicaid
https://www.mdedge.com/emergencymedicine/article/193150/suicide-trends-among-youth-medicaid

Jan 24th, 2019 - Younger people who are enrolled in Medicaid who commit suicide are disproportionately female, younger, and more likely to die by hanging. The risk for acute myeloid leukemia and myeloma is higher for breast cancer survivors, matched transplant imp.

Matched transplant improves stroke risk indicator in sickle cell anemia
https://www.mdedge.com/pediatrics/article/193003/anemia/matched-transplant-improves-stroke-risk-indicator-sickle-cell
Andrew D. Bowser

Jan 22nd, 2019 - In children with sickle cell anemia, matched sibling donor transplants improved an indicator of stroke risk in a multicenter French study, suggesting that this intervention may improve outcomes related to cerebral vasculopathy. Matched sibling don.

see more →

Patient Education  15 results see all →